A 50-year-old Russian accountant successfully received an innovative CAR-T cell therapy after failing a series of standard treatments. The patient was initially diagnosed with diffuse large B-cell lymphoma in 2019. The disease relapsed despite multiple rounds of treatment including autologous hematopoietic stem cell transplant,and had high resistance to traditional therapies. Facing desperate conditions,including inferior blood parameters and no response to traditional therapies, the patient switched to CAR-T cell therapy.

Despite major challenges such as COVID-19 pandemic during treatment, the patient successfully overcame the virus with oral antiviral therapy and continued CAR-T cell refusion. The patient safely passed the critical period with the help of hormones, antibiotics, and other supportive treatments albeit a series of serious side effects after treatment. The treatment results showed a significant reduction in the lymphoma cell count in the peripheral blood and bone marrow, demonstrating the effectiveness of CAR-T therapy. The patient was discharged uneventfully and returned to Russia in January 2024.